Venetoclax
Small molecule
Evidence outlook
Approved: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Multiple Myeloma · Phase 3 · investigational in the US
Also approved (2)
- Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL): in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor,...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06073730 NCT06073730 · Acute Myeloid Leukemia Registry: NCT06073730 | 3 | Event-free survival (up to 12 months) 2025-12-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 5 more trials
NCT05654194 NCT05654194 · Acute Myeloid Leukemia Registry: NCT05654194 | 3 | Rate of the bone marrow complete response (after completion of one induction courses (1st Induction Course is 28 days) and before starting of the 2nd cycle) 2024-09-29 | Results not posted; external-source review pending | not yet graded | link ↗ |
Viale-a NCT02993523 · Acute Myeloid Leukemia This was a randomized, quadruple-blind, placebo-controlled phase 3 trial whose primary endpoint, overall survival, was met with a statistically significant improvement for venetoclax plus azacitidine. A power calculation was reported in the protocol and statistical analysis plan, and 431 participants were randomized against a planned 400. Registry: NCT02993523 | 3 | Overall Survival (OS) (From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)); Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi) (From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)) 2021-12-01 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT02203773 NCT02203773 · Acute Myeloid Leukemia Registry: NCT02203773 | 1 | Number of Participants Experiencing Adverse Events (AEs) (Measured up to 1 year after the last subject last dose); Maximum observed plasma concentration (Cmax) (For approximately 5 days following a single dose of ABT-199.); Time to Cmax (peak time, Tmax), (For approximately 5 days following a single dose of ABT-199.); The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC0-24) (For approximately 5 days following a single dose of ABT-199.); Half-Life (t1/2) (For approximately 5 days following a single dose of ABT-199.); Clearance (CL) (For approximately 5 days following a single dose of ABT-199.); Complete Remission Rate (Measured up to 1 year after the last subject last dose); Complete Remission with incomplete blood count recovery rate (Measured up to 1 year after the last subject last dose); Overall Response Rate (Measured up to 1 year after the last subject last dose); Overall Survival (Measured up to 1 year after the last subject last dose) 2022-06-16 | Label-reported response: For the 17 patients treated with VENCLEXTA in combination with azacitidine, the CR rate was 35% (95% CI: 14%, 62%). | not yet graded | link ↗ |
NCT03069352 NCT03069352 · Acute Myeloid Leukemia This was a randomized, quadruple-blind, placebo-controlled phase 3 trial, but its primary endpoint, overall survival, did not reach statistical significance at the primary analysis (hazard ratio 0.749, p=0.114). It is well-designed evidence of an unclear survival effect rather than strong evidence of benefit. Registry: NCT03069352 | 3 | Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.) 2019-02-15 | Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) | Partial signal | link ↗ |
NCT02287233 NCT02287233 · Acute Myeloid Leukemia The study was non-randomized, open-label, and had no placebo or active comparator; it used dose escalation followed by expansion in 94 participants. Although overall response was reported as 54.9% among 82 participants at the 600-mg dose, the single-arm design does not establish comparative efficacy, so this is weak evidence for venetoclax. Registry: NCT02287233 | 1/2 | Phase 1: Number of Participants With Dose-limiting Toxicities (Up to 28 days (Cycle 1)); Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax (Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)); Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax (Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)); Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax (Cycle 1, Day 10 at predose and 2, 4, 6, 8, and 24 hours postdose (venetoclax with LDAC); Cycle 1, Day 18 at predose, 2, 4, 6, 8, and 24 hours postdose (venetoclax alone)); Phase 1: Maximum Observed Plasma Concentration (Cmax) of Cytarabine (Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.); Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Cytarabine (Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.); Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to Last Measurable Concentration (AUCt) of Cytarabine (Cycle 1, Day 1 and Day 10 at pre-dose and at 15 and 30 minutes and 1, 3, 6 hours post-dose.); Overall Response Rate (Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (From first dose of study drug until 30 days after last dose of study drug; median (minimum, maximum) duration of treatment was 4.1 (0.2, 62.8) months overall.) 2021-08-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (307)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (128)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (186)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (38)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Appears in other studies (6)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other BCL-2 drugs
Sonrotoclax, Lisaftoclax, Mesutoclax, FCN-338, Surzetoclax and 4 more. Compare all 10 BCL-2 drugs
This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Venetoclax: this drug | Approved | Small molecule | BCL-2 | Reliable signal | NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed | |
| Azacitidine (Onureg) | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | Weak signal | NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Enasidenib (Idhifa) | Approved | Small molecule | IDH2 | Partial signal | NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed | |
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | Partial signal | NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients. | |
| Gilteritinib | Approved | Small molecule | FLT3 | Partial signal | NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed | |
| Glasdegib | Approved | Small molecule | Hedgehog Pathway Inhibitor | Partial signal | No reviewed efficacy summary in this indication | |
| Ivosidenib (Tibsovo) | Approved | Small molecule | Mutant IDH1 | Reliable signal | NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) | |
| Midostaurin (Rydapt) | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | Weak signal | NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results). | |
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | Weak signal | Featured results are safety only in this race | |
| Orca-T (TREGZI) | Approved | Cell therapy | Allogeneic engineered T-cell immunotherapy | Partial signal | NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5) | |
| Quizartinib | Approved | Small molecule | FLT3 | Reliable signal | NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Sargramostim (Leukine) | Approved | Protein / enzyme therapeutic | GM-CSF receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tretinoin (Vesanoid) | ApprovedUS marketing discontinued | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | not yet graded | NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending | |
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | Partial signal | NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1). | |
| Ziftomenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 | Partial signal | NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001 | |
| Arsenic Trioxide (QTX-2101) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | not yet graded | No reviewed efficacy summary in this indication | |
| Arsenic Trioxide (SDK001) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | Partial signal | No reviewed efficacy summary in this indication | |
| Azacitidine | Phase 3 | Small molecule | DNMT1 (DNA methyltransferase 1) | Partial signal | NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed | |
| Bleximenib | Phase 3 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Clifutinib Besylate | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Crenolanib | Phase 3 | Small molecule | FLT3 (including D835/ITD mutants), also PDGFR-alpha/beta | Reliable signal | NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145) | |
| Galinpepimut-S | Phase 3 | Vaccine | WT1 (Wilms Tumor-1 protein) | Weak signal | NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47% | |
| Inobrodib | Phase 3(overall) | Small molecule | CBP/p300 (bromodomain) | not yet graded | No reviewed efficacy summary in this indication | |
| Lisaftoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mocravimod | Phase 3 | Small molecule | Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruserontinib | Phase 3 | Small molecule | FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes) | Partial signal | No reviewed efficacy summary in this indication | |
| XY0206 | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Annamycin | Phase 2/3 | Small molecule | Topoisomerase II (TOP2) | not yet graded | No reviewed efficacy summary in this indication | |
| BL-M11D1 | Phase 2/3 | Antibody–drug conjugate | CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| Pivekimab Sunirine (Decnupaz) | Phase 2/3 | Antibody–drug conjugate | CD123 | not yet graded | No reviewed efficacy summary in this indication | |
| Cusatuzumab | Phase 2 | Monoclonal antibody | CD70 | Weak signal | NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38 | |
| FCN-338 | Phase 2(overall) | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Lintuzumab-Ac225 | Phase 2 | Radiopharmaceutical | CD33 | Weak signal | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 2 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | Weak signal | NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months | |
| Prexigebersen | Phase 2 | RNA / oligonucleotide | GRB2 (growth factor receptor-bound protein 2) mRNA | Weak signal | Featured results are safety only in this race | |
| Romaciclib | Phase 2 | Small molecule | CDK8 / CDK19 | Weak signal | NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response | |
| Sonrotoclax (Beqalzi) | Phase 2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tagraxofusp | Phase 2 | Protein / enzyme therapeutic | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| Vididencel | Phase 2 | Vaccine | Allogeneic dendritic cell vaccine | Weak signal | NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported). | |
| AB8939 | Phase 1/2 | Small molecule | Tubulin | not yet graded | No reviewed efficacy summary in this indication | |
| ABD-3001 | Phase 1/2 | Small molecule | ALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1) | not yet graded | No reviewed efficacy summary in this indication | |
| Alrizomadlin | Phase 1/2 | Small molecule | MDM2 | Weak signal | No reviewed efficacy summary in this indication | |
| ARD103 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3632 | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Bexmarilimab | Phase 1/2 | Monoclonal antibody | Clever-1 | not yet graded | No reviewed efficacy summary in this indication | |
| BG1805 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| BSB-1001 | Phase 1/2 | Cell therapy | HA-1 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| CART84 | Phase 1/2 | Cell therapy | CD84 | not yet graded | No reviewed efficacy summary in this indication | |
| CCTx-001 | Phase 1/2 | Cell therapy | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| CD123 Targeted CAR-NK Cells | Phase 1/2 | Cell therapy | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| CD123 / CD33 CART | Phase 1/2 | Cell therapy | CD123 / CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-049 | Phase 1/2 | Multispecific antibody | FLT3, CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Debio 1562M | Phase 1/2 | Antibody–drug conjugate | CD37 | not yet graded | No reviewed efficacy summary in this indication | |
| Emavusertib | Phase 1/2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enzomenib | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Ligufalimab | Phase 1/2 | Monoclonal antibody | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| Mobinitinib | Phase 1/2 | Small molecule | FLT3 / Aurora kinase A and B | not yet graded | No reviewed efficacy summary in this indication | |
| MRX-2843 | Phase 1/2 | Small molecule | Flt3/MerTK | Weak signal | No reviewed efficacy summary in this indication | |
| Ocifisertib | Phase 1/2 | Small molecule | PLK4 (Polo-like kinase 4) | Weak signal | Featured results are safety only in this race | |
| Olverembatinib | Phase 1/2 | Small molecule | BCR-ABL (also AKT, c-Kit, ERK) | not yet graded | No reviewed efficacy summary in this indication | |
| OrcaGraft (Orca-Q) | Phase 1/2 | Cell therapy | Treg-enriched allogeneic haematopoietic stem cell graft | not yet graded | No reviewed efficacy summary in this indication | |
| Rogocekib | Phase 1/2 | Small molecule | CLK (CDC-like kinase family) | not yet graded | No reviewed efficacy summary in this indication | |
| TGRX-814 | Phase 1/2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-21447 | Phase 1(overall) | Small molecule | BCL-2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FXS0683 | Phase 1 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Lonitoclax | Phase 1 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 69 furthest-along competitors are listed; 62 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(334 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Venetoclax to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (34)
November 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
December 2026 (29)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (134)
January 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2027 (30)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (85)
January 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2028 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (4)
What to watch
What to watch
What to watch
What to watch
May 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2028 (1)
What to watch
September 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2028 (3)
What to watch
What to watch
What to watch
December 2028 (15)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (38)
January 2029 (3)
What to watch
What to watch
What to watch
February 2029 (2)
March 2029 (3)
April 2029 (3)
What to watch
What to watch
What to watch
May 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
June 2029 (4)
What to watch
What to watch
What to watch
What to watch
July 2029 (4)
What to watch
What to watch
What to watch
August 2029 (1)
What to watch
September 2029 (2)
October 2029 (1)
What to watch
December 2029 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (24)
January 2030 (2)
March 2030 (1)
What to watch
April 2030 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
May 2030 (1)
What to watch
June 2030 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2030 (1)
What to watch
August 2030 (1)
What to watch
September 2030 (3)
What to watch
What to watch
What to watch
December 2030 (3)
What to watch
What to watch
What to watch
2031 (8)
February 2031 (1)
What to watch
May 2031 (1)
What to watch
June 2031 (2)
September 2031 (2)
October 2031 (1)
What to watch
November 2031 (1)
What to watch
2032 (6)
February 2032 (2)
What to watch
What to watch
March 2032 (1)
What to watch
June 2032 (2)
December 2032 (1)
What to watch
2033 (1)
May 2033 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
2035 (1)
December 2035 (1)
What to watch
2038 (1)
December 2038 (1)
What to watch
2040 (1)
December 2040 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent